Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Hesham ElHalawani & Omar Abdel-Rahman. (2015) Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers. Therapeutics and Clinical Risk Management 11, pages 1123-1132.
Read now
Read now
Qing Ma, Li-Yan Gu, Yao-Yao Ren, Li-Li Zeng, Ting Gong & Dian-Sheng Zhong. (2015) Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis. OncoTargets and Therapy 8, pages 2361-2374.
Read now
Read now
Omar Abdel-Rahman & Mona Fouad. (2015) Irinotecan-based regimens for recurrent glioblastoma multiform: a systematic review. Expert Review of Neurotherapeutics 15:11, pages 1255-1270.
Read now
Read now
Omar Abdel-Rahman & Mohamed kelany. (2015) Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. Expert Review of Respiratory Medicine 9:5, pages 533-549.
Read now
Read now
Articles from other publishers (17)
Dylan Haynes, Eric E. Morgan & Emily Y. Chu. (2023) Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings. Human Pathology.
Crossref
Crossref
Rose Parisi, Hemali Shah, Neil H. Shear, Michael Ziv, Alina Markova & Roni P. Dodiuk-Gad. (2023) A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy. Biomedicines 11:2, pages 323.
Crossref
Crossref
Marina L.D. Pera & Guilherme F. Speretta. (2023) Effects of Exercise on Vascular Toxicity Associated with Breast Cancer
Treatment: A Narrative Review. Current Vascular Pharmacology 21:1, pages 42-50.
Crossref
Crossref
Sharon Elad, Noam Yarom, Yehuda Zadik, Michal Kuten‐Shorrer & Stephen T. Sonis. (2021) The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA: A Cancer Journal for Clinicians 72:1, pages 57-77.
Crossref
Crossref
Riyad N. H. Seervai, Woo Cheal Cho, Emily Y. Chu, Mario L. Marques‐Piubelli, Debora A. Ledesma, Kristen Richards, Meghan M. Heberton, Kelly C. Nelson, Priyadharsini Nagarajan, Carlos A. Torres‐Cabala, Victor G. Prieto & Jonathan L. Curry. (2021) Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy. Journal of Cutaneous Pathology 49:1, pages 61-81.
Crossref
Crossref
Allison Zarbo & Anna Axelson. 2020. Practical Guide to Dermatology. Practical Guide to Dermatology
289
306
.
Jian Li, Ming Wang, Bo Zhang, Xin Wu, Tian-Long Lin, Xiu-Feng Liu, Ye Zhou, Xin-Hua Zhang, Hao Xu, Li-Jing Shen, Jing Zou, Ping Lu, Dong Zhang, Wei-Jun Gu, Mei-Xia Zhang, Jian Pan & Hui Cao. (2018) Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. World Journal of Gastroenterology 24:46, pages 5189-5202.
Crossref
Crossref
Li Gong, Marilyn M. Giacomini, Craig Giacomini, Michael L. Maitland, Russ B. Altman & Teri E. Klein. (2017) PharmGKB summary. Pharmacogenetics and Genomics 27:6, pages 240-246.
Crossref
Crossref
Hesham Elhalawani, Muhammad Heiba & Omar Abdel-Rahman. (2017) Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta-analysis. Clinical Genitourinary Cancer 15:3, pages e325-e335.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
641
693
.
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
199
219
.
Omar Abdel-Rahman, Hesham ElHalawani & Hoda Ahmed. (2015)
Risk of selected dermatological toxicities in cancer patients treated with
MEK
inhibitors: a comparative systematic review and meta-analysis
. Future Oncology 11:24, pages 3307-3319.
Crossref
Crossref
Omar Abdel-Rahman & Hesham ElHalawani. (2015) Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis. Future Oncology 11:21, pages 2949-2961.
Crossref
Crossref
Raafat S. Alameddine, Ahmad Sharif Yakan, Hadi Skouri, Deborah Mukherji, Sally Temraz & Ali Shamseddine. (2015) Cardiac and vascular toxicities of angiogenesis inhibitors: The other side of the coin. Critical Reviews in Oncology/Hematology 96:2, pages 195-205.
Crossref
Crossref
Omar Abdel-Rahman, Hamdy A Azim, Sameh Mikhail & Mohamed E Salem. (2015) New hope on the horizon for patients with metastatic colorectal cancer. Colorectal Cancer 4:6, pages 229-239.
Crossref
Crossref
Omar Abdel-Rahman, Hesham ElHalawani & Mona Fouad. (2015) Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncology 11:17, pages 2471-2484.
Crossref
Crossref
Omar Abdel-Rahman & Mona Fouad. (2015) Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review. Future Oncology 11:12, pages 1829-1843.
Crossref
Crossref